Examining the safety profile of a standard dose tranexamic acid regimen in spine surgery
Neurosurgical Focus · 2023
DOI: 10.3171/2023.7.focus23384 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurosurgical Focus, 2023. Verfasst von Joshua Setliff und 9 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Orthopaedic Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. Hauptthemen laut MEDLINE: Tranexamic Acid, Antifibrinolytic Agents, Thromboembolism. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 68 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE Perioperative blood loss during spinal surgery is associated with complications and in-hospital mortality. Weight-based administration of tranexamic acid (TXA) has the potential to reduce blood loss and related complications in spinal surgery; however, evidence for standardized dosing is lacking. The purpose of this study was to evaluate the impact of a standardized preoperative 2 g bolus TXA dosing regimen on perioperative transfusion, blood loss, thromboembolic events, and postoperative outcomes in spine surgery patients. METHODS An institutional review board approved this retrospective review of prospectively enrolled adult spine patients (> 18 years of age). Patients were included who underwent elective and emergency spine surgery between September 2018 and July 2021. Patients who received a standardized 2 g dose of TXA were compared to patients who did not receive TXA. The primary outcome measure was perioperative transfusion. Secondary outcomes included estimated blood loss and thromboembolic or other perioperative complications. Descriptive statistics were calculated, and continuous variables were analyzed with the two-tailed independent t-test, while categorical variables were analyzed with the Fisher’s exact test or chi-square test. Stepwise multivariate regression analysis was performed to examine independent risk factors for perioperative outcomes. RESULTS TXA was administered to 353 of 453 (78%) patients, and there were no demographic differences between groups. Although the TXA group had more operative levels and a longer operative time, the transfusion rate was not different between the TXA and no-TXA groups (7.4% vs 8%, p = 0.83). Stepwise multivariate regression found that the number of operative levels was an independent predictor of perioperative transfusion and that both operative levels and operative time were correlated with estimated blood loss. TXA was not identified as an independent predictor of any postoperative complication. CONCLUSIONS A standardized preoperative 2 g bolus TXA dosing regimen was associated with an excellent safety profile, and despite increased case complexity in terms of number of operative levels and operative time, patients treated with TXA did not require more blood transfusions than patients not treated with TXA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 1Department of Orthopaedic Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
- 3Pittsburgh Orthopaedic Spine Research Group, Pittsburgh, Pennsylvania.
- 2Department of Orthopaedic Surgery, Montefiore Medical Center, New York, New York; and.
Zitieren
APA
Setliff, J., Dalton, J., Sadhwani, S., Tang, M. Y., Mirvish, A., Adida, S., Wawrose, R., Lee, J. Y., Fourman, M. S., & Shaw, J. D. (2023). Examining the safety profile of a standard dose tranexamic acid regimen in spine surgery. Neurosurgical Focus. https://doi.org/10.3171/2023.7.focus23384
Vancouver
Setliff J, Dalton J, Sadhwani S, Tang MY, Mirvish A, Adida S, et al. Examining the safety profile of a standard dose tranexamic acid regimen in spine surgery. Neurosurgical Focus. 2023. doi:10.3171/2023.7.focus23384
BibTeX
@article{Setliff2023,
author = {Setliff, Joshua and Dalton, Jonathan and Sadhwani, Shaan and Tang, Melissa Yunting and Mirvish, Asher and Adida, Samuel and Wawrose, Richard and Lee, Joon Y and Fourman, Mitchell S and Shaw, Jeremy D},
title = {Examining the safety profile of a standard dose tranexamic acid regimen in spine surgery},
journal = {Neurosurgical Focus},
year = {2023},
doi = {10.3171/2023.7.focus23384}
}
EUVIMED